The efficacy of PD-1 immune therapy has also been shown to depend on interferon gamma (IFNγ) sensing by tumor cells in the tumor microenvironment, which can be regulated by tyrosine-protein phosphatase non-receptor type 2 (Ptpn2) (10, 11). This evidence concerns the gene PTPN2 and neoplasm.